Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy, in Patients With Metastatic Renal Cell Carcinoma in Daily Clinical Practice
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SPAZO
- 09 Dec 2015 Results published in the Annals of Oncology
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.